No Data
SymbolStock Name
PriceChg% ChgVolumeTurnoverOpenPre CloseHighLowMarket CapFloat CapSharesShs Float5D % Chg10D % Chg20D % Chg60D % Chg120D % Chg250D % Chg% Year-to-dateDiv YieldTTMTurnover RatioP/E (TTM)P/E (Static)AmplitudeIndustry
Watchlist
No Data
FibroBiologics Resolves Commitments Through Share Issuance Agreement
FibroBiologics Price Target Announced at $12.00/Share by Rodman & Renshaw
Rodman & Renshaw Initiates Coverage On FibroBiologics With Buy Rating, Announces Price Target of $12
FibroBiologics Files Patent Application for a Cell-based Therapeutic for the Treatment Of Splenomegaly
Express News | Fibrobiologics Files Patent Application for a Cell-Based Therapeutic for the Treatment of Splenomegaly
Promising Developments and Financial Stability Highlight FibroBiologics' Near-Term Opportunities